Any feedback?
Please rate this page
(search_result.php)
(0/150)

BRENDA support

Refine search

Search Crystallization (Commentary)

show results
Don't show organism specific information (fast!)
Search organism in taxonomic tree (slow, choose "exact" as search mode, e.g. "mammalia" for rat,human,monkey,...)
(Not possible to combine with the first option)
Refine your search

Search term:

Results 1 - 9 of 9
EC Number Crystallization (Commentary)
Show all pathways known for 3.2.2.5Display the word mapDisplay the reaction diagram Show all sequences 3.2.2.5C-terminal glycohydrolase domain of SPN (residues 191-451) in complex with IFS, vapor diffusion method, using 20%-25% (w/v) PEG 8K and 100 mM Tris-HCl (pH 8.0), at 22°C
Show all pathways known for 3.2.2.5Display the word mapDisplay the reaction diagram Show all sequences 3.2.2.5CD38 in complex with ribosyl-2'-fluoro-deoxy-adenosine diphosphate or arabinosyl-2'-fluoro-deoxy-adenosine diphosphate ribose, soaking crystals in a solution containing either 5.2 mM inhibitor, and 100 mM MES, pH 6.0, 15% PEG 4000, and 30% glycerol, X-ray diffraction structure determination and analysis at 1.75-2.0 A resolution
Show all pathways known for 3.2.2.5Display the word mapDisplay the reaction diagram Show all sequences 3.2.2.5in complex with effector Tni2, to 1.7 A resolution
Show all pathways known for 3.2.2.5Display the word mapDisplay the reaction diagram Show all sequences 3.2.2.5purified recombinant selenomethionine-labeled enzyme C-terminal domain (residues 193-451) in complex with the full-length inhibitor IFS, sitting drop vapor-diffusion method, mixing of 0.001 ml of protein solution with 0.001 ml of reservoir solution of 20% w/v tacsimate, pH 4.0, and 20% w/v PEG 3350, 22°C, X-ray diffraction structure determination and analysis at 1.70 A resolution, single-wavelength anomalous diffraction, modelling
Show all pathways known for 3.2.2.5Display the word mapDisplay the reaction diagram Show all sequences 3.2.2.5purified recombinant wild-type and mutant enzymes, mixing of 0.001 ml of protein sample with 0.001 ml of precipitant solution containing 0.1 M imidazole, pH 7.5, and 12-24% PEG 4000, X-ray diffraction structure determination and analysis at 1.75-2.18 A resolution
Show all pathways known for 3.2.2.5Display the word mapDisplay the reaction diagram Show all sequences 3.2.2.5to 1.4 A resolution, in complex with binding protein Tsi6
Show all pathways known for 3.2.2.5Display the word mapDisplay the reaction diagram Show all sequences 3.2.2.5wild-type and mutant E226Q in complex with cyclic ADP-ribose at 1.5 A resolution, with cyclic GDP-ribose at 1.68 A, and with NGD+ at 2.1A. Binding of cyclic ADP-ribose or cyclic GDP-ribose induce structural changes in the dipeptide E146D147 of 2.7 A. Resiudue E226 is critical in catalysis and in positioning of cyclic ADP-ribose
Show all pathways known for 3.2.2.5Display the word mapDisplay the reaction diagram Show all sequences 3.2.2.5wild-type and mutant E226Q in complex with inhibitor N1-cyclic inosine diphosphate ribose at 1.7 and 1.176 A resolution, respectively
Show all pathways known for 3.2.2.5Display the word mapDisplay the reaction diagram Show all sequences 3.2.2.5wild-type and mutant E226Q in complex with NAD+, NGD+, or GDP-ribose. The reaction intermediate is stabilized by polar interactions with the catalytic residue E226 rather than by a covalent linkage
Results 1 - 9 of 9